Literature DB >> 27282153

A novel anticancer agent icaritin inhibited proinflammatory cytokines in TRAMP mice.

Jimeng Hu1, Tian Yang1, Hua Xu1, Mengbo Hu1, Hui Wen1, Haowen Jiang2.   

Abstract

PURPOSE: We aimed to investigate whether icaritin (ICT) would inhibit serum proinflammatory cytokines and postpone prostate cancer (PCa) development and progression in both normal diet and high-fat diet (HFD) transgenic adenocarcinoma mouse prostate (TRAMP) mice.
METHODS: TRAMP mice were randomly divided into four groups: normal diet with/without ICT group and HFD with/without ICT group. Each TRAMP mouse received intraperitoneal injection of ICT solution at the dose of 30 mg/kg 5 times per week.
RESULTS: ICT treatment could significantly increase the survival when compared with those in normal diet group (P = 0.015, log-rank test) and HFD group (P = 0.009, log-rank test). Proinflammatory cytokine levels, including IL-1α, IL-1β, IL-6, and TNF-α, were decreased more or less in ICT-treated TRAMP mice. Moreover, significant higher inflammation scores were detected in normal diet group and HFD group compared with their relevant ICT treatment groups (P = 0.026 and P = 0.006, respectively). Meanwhile, the incidences of well-differentiated tumor tissue in two ICT treatment groups (39.13 and 31.82 %) were moderately higher than control groups (29.41 and 20.00 %, respectively), though no significant difference was observed.
CONCLUSIONS: Taken together, our findings indicate that ICT could inhibit the development and progression of PCa in TRAMP mice via inhibiting proinflammatory cytokines.

Entities:  

Keywords:  High-fat diet; Icaritin; Proinflammatory cytokines; Prostate cancer; TRAMP

Mesh:

Substances:

Year:  2016        PMID: 27282153     DOI: 10.1007/s11255-016-1341-9

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  29 in total

1.  Interleukin-6: a potential biomarker of resistance to multitargeted receptor tyrosine kinase inhibitors in castration-resistant prostate cancer.

Authors:  Alexander Kutikov; Peter Makhov; Konstantin Golovine; Daniel J Canter; Mohit Sirohi; Ryan Street; Jay Simhan; Robert G Uzzo; Vladimir M Kolenko
Journal:  Urology       Date:  2011-10       Impact factor: 2.649

2.  Insulin-Like growth factor 1 related pathways and high-fat diet promotion of transgenic adenocarcinoma mouse prostate (TRAMP) cancer progression.

Authors:  H Xu; H W Jiang; Q Ding
Journal:  Actas Urol Esp       Date:  2014-10-28       Impact factor: 0.994

Review 3.  Genetic polymorphism of interleukin-1A (IL-1A), IL-1B, and IL-1 receptor antagonist (IL-1RN) and prostate cancer risk.

Authors:  Hua Xu; Qiang Ding; Hao-Wen Jiang
Journal:  Asian Pac J Cancer Prev       Date:  2014

4.  Prolonged treatment with bicalutamide induces androgen receptor overexpression and androgen hypersensitivity.

Authors:  Hiromitsu Kawata; Nobuyuki Ishikura; Miho Watanabe; Ayako Nishimoto; Toshiaki Tsunenari; Yuko Aoki
Journal:  Prostate       Date:  2010-05-15       Impact factor: 4.104

5.  Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice.

Authors:  Lauren Wallner; Jinlu Dai; June Escara-Wilke; Jian Zhang; Zhi Yao; Yi Lu; Mohit Trikha; Jeffrey A Nemeth; Mohamed H Zaki; Evan T Keller
Journal:  Cancer Res       Date:  2006-03-15       Impact factor: 12.701

6.  Icaritin induces AML cell apoptosis via the MAPK/ERK and PI3K/AKT signal pathways.

Authors:  Qihui Li; Lei Huai; Cuiping Zhang; Cuicui Wang; Yujjao Jia; Yirui Chen; Pei Yu; Houcai Wang; Qing Rao; Min Wang; Jianxiang Wang
Journal:  Int J Hematol       Date:  2013-04-03       Impact factor: 2.490

7.  Metastatic prostate cancer in a transgenic mouse.

Authors:  J R Gingrich; R J Barrios; R A Morton; B F Boyce; F J DeMayo; M J Finegold; R Angelopoulou; J M Rosen; N M Greenberg
Journal:  Cancer Res       Date:  1996-09-15       Impact factor: 12.701

8.  Association between tumor necrosis factor in serum and cachexia in patients with prostate cancer.

Authors:  J Nakashima; M Tachibana; M Ueno; A Miyajima; S Baba; M Murai
Journal:  Clin Cancer Res       Date:  1998-07       Impact factor: 12.531

9.  Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer.

Authors:  V Michalaki; K Syrigos; P Charles; J Waxman
Journal:  Br J Cancer       Date:  2004-06-14       Impact factor: 7.640

10.  Icaritin inhibits JAK/STAT3 signaling and growth of renal cell carcinoma.

Authors:  Shasha Li; Saul J Priceman; Hong Xin; Wang Zhang; Jiehui Deng; Yong Liu; Jiabin Huang; Wenshan Zhu; Mingjie Chen; Wei Hu; Xiaomin Deng; Jian Zhang; Hua Yu; Guangyuan He
Journal:  PLoS One       Date:  2013-12-06       Impact factor: 3.240

View more
  4 in total

1.  Icaritin inhibits PLK1 to activate DNA damage response in NK/T cell lymphoma and increases sensitivity to GELOX regime.

Authors:  Canjing Zhang; Huiwen Xu; Xianxian Sui; Lina Chen; Bobin Chen; Haozhen Lv; Songmei Wang; Xuanyi Wang
Journal:  Mol Ther Oncolytics       Date:  2022-05-04       Impact factor: 6.311

2.  Anticancer effect of icaritin on prostate cancer via regulating miR-381-3p and its target gene UBE2C.

Authors:  Jimeng Hu; Xiaobo Wu; Chen Yang; Khalid Rashid; Chenkai Ma; Mengbo Hu; Qiang Ding; Haowen Jiang
Journal:  Cancer Med       Date:  2019-10-24       Impact factor: 4.452

3.  Icaritin Induces Anti-tumor Immune Responses in Hepatocellular Carcinoma by Inhibiting Splenic Myeloid-Derived Suppressor Cell Generation.

Authors:  Huimin Tao; Mingyu Liu; Yuan Wang; Shufeng Luo; Yongquan Xu; Bin Ye; Limin Zheng; Kun Meng; Lian Li
Journal:  Front Immunol       Date:  2021-02-26       Impact factor: 7.561

4.  A comparative study on the in vitro and in vivo antitumor efficacy of icaritin and hydrous icaritin nanorods.

Authors:  Haowen Li; Yijing Li; Hui Ao; Jingxin Fu; Yifei Guo; Meihua Han; Xueying Yan; Xi Chen; Xiangtao Wang
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.